Page 20 - Diagnosis and clinical consequences of cachexia in patients with advanced cancer Susanne Blauwhoff-Buskermolen

Chapter 1
21. Argiles JM, Busquets S, Stemmler B, Lopez-Soriano FJ. Cancer cachexia: understanding the molecular basis. Nat Rev Cancer 2014;14:754-62.
22. Onesti JK, Guttridge DC. In ammation based regulation of cancer cachexia. Biomed Res Int 2014;2014:168407.
23. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999;402:656-60.
24. Shimizu Y, Nagaya N, Isobe T, Imazu M, Okumura H, Hosoda H, Kojima M, Kangawa K, Kohno N. Increased plasma ghrelin level in lung cancer cachexia. Clin Cancer Res 2003;9:774-8.
25. Karapanagiotou EM, Polyzos A, Dilana KD, Gratsias I, Boura P, Gkiozos I, Syrigos KN. Increased serum levels of ghrelin at diagnosis mediate body weight loss in non-small cell lung cancer (NSCLC) patients. Lung Cancer 2009;66:393-8.
26. Mondello P, Lacquaniti A, Mondello S, Bolignano D, Pitini V, Aloisi C, Buemi M. Emerging markers of cachexia predict survival in cancer patients. BMC Cancer 2014;14:828.
27. Wolf I, Sadetzki S, Kanety H, Kundel Y, Pariente C, Epstein N, Oberman B, Catane R, Kaufman B, Shimon I. Adiponectin, ghrelin, and leptin in cancer cachexia in breast and colon cancer patients. Cancer 2006;106:966-73.
28. Huang Q, Fan YZ, Ge BJ, Zhu Q,Tu ZY. Circulating ghrelin in patients with gastric or colorectal cancer. Dig Dis Sci 2007;52:803-9.
29. D’Onghia V, Leoncini R, Carli R, Santoro A, Giglioni S, Sorbellini F, Marzocca G, Bernini A, Campagna S, Marinello E et al. Circulating gastrin and ghrelin levels in patients with colorectal cancer: correlation with tumour stage, Helicobacter pylori infection and BMI. Biomed Pharmacother 2007;61:137-41.
30. Doehner W, Anker SD. Cardiac cachexia in early literature: a review of research prior to Medline. Int J Cardiol 2002;85:7-14.
31. von Haehling S, Anker SD. Prevalence, incidence and clinical impact of cachexia: facts and numbers- update 2014. J Cachexia Sarcopenia Muscle 2014;5:261-3.
32. Ryan A, Power D, Daly L, Cushen S, Ni Bhuachalla E, Prado C. Cancer-associated malnutrition, cachexia and sarcopenia: the skeleton in the hospital closet 40 years later. Proc Nutr Soc 2016;1-13.
33. Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, Jatoi A, Kalantar-Zadeh K, Lochs H, Mantovani G et al. Cachexia: a new de nition. Clin Nutr 2008;27:793-9.
34. Blum D, Stene G, Solheim T, Fayers P, Hjermstad M, Baracos V, Fearon K, Strasser F, Kaasa S.Validation of the Consensus-De nition for Cancer Cachexia and evaluation of a classi cation model - A study based on data from an international multicentre project (EPCRC-CSA). Ann Oncol 2014.
35. Kruizenga HM,Seidell JC,deVet HC,Wierdsma NJ,van Bokhorst-de van der Schueren MA.Development and validation of a hospital screening tool for malnutrition:the short nutritional assessment questionnaire (SNAQ). Clin Nutr 2005;24:75-82.
36. Dewys WD, Begg C, Lavin PT, Band PR, Bennett JM, Bertino JR, Cohen MH, Douglass HO, Jr., Engstrom PF, Ezdinli EZ et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 1980;69:491-7.
37. Andreyev HJ, Norman AR, Oates J, Cunningham D. Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer 1998;34:503-9.
38. Persson C, Glimelius B. The relevance of weight loss for survival and quality of life in patients with advanced gastrointestinal cancer treated with palliative chemotherapy. Anticancer Res 2002;22:3661-8.
39. Barret M, Antoun S, Dalban C, Malka D, Mansourbakht T, Zaanan A, Latko E,Taieb J. Sarcopenia is linked to treatment toxicity in patients with metastatic colorectal cancer. Nutr Cancer 2014;66:583-9.
40. Mir O, Coriat R, Blanchet B, Durand JP, Boudou-Rouquette P, Michels J, Ropert S,Vidal M, Pol S, Chaussade S et al. Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. PLoS One 2012;7:e37563.
41. Huillard O, Mir O, Peyromaure M,Tlemsani C, Giroux J, Boudou-Rouquette P, Ropert S, Delongchamps NB, Zerbib M, Goldwasser F. Sarcopenia and body mass index predict sunitinib-induced early dose- limiting toxicities in renal cancer patients. Br J Cancer 2013;108:1034-41.
42. Ali R, Baracos V, Sawyer M, Bianchi L, Roberts S, Assenat E, Mollevi C, Senesse P. Lean body mass as an independent determinant of dose-limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens. Cancer Med 2016;5:607-16
18